Article Figures & Data
Figures
- FIGURE 1.
Comparison of hematologic lab results for hemoglobin (A), white blood cells (WBC) (B), thrombocytes (C), and creatinine (D) before and after 177Lu-PSMA-I&T rechallenge. CTCAE = Common Terminology Criteria for Adverse Events.
- FIGURE 2.
Waterfall plot of maximum PSA responses during 177Lu-PSMA-I&T rechallenge as compared with baseline levels.
- FIGURE 3.
Swimmer plot demonstrating mCRPC treatment duration and maximum PSA response at 177Lu-PSMA-I&T rechallenge.
Tables
Characteristic Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Primary diagnosis Date 2008 2001 2002 2012 2004 2008 2005 2006 Initial PSA (ng/mL) 40 6 24 26 29 7 72 14 Gleason score 9 9 6 7a 9 9 0 7b Metastases LN — Bone LN, bone LN — LN — Prior treatments Primary therapy (RP/RT) +/+ +/+ −/− −/+ +/+ +/+ +/+ +/+ mCRPC therapies Drugs Docetaxel, abiraterone enzalutamide, 223Ra Docetaxel* cabazitaxel, abiraterone, others† Docetaxel, abiraterone enzalutamide, 223Ra Docetaxel, abiraterone enzalutamide Docetaxel*, abiraterone enzalutamide Docetaxel, abiraterone enzalutamide Docetaxel, abiraterone enzalutamide Abiraterone enzalutamide Lines 4 8 4 3 4 3 3 2 177Lu-PSMA-I&T Initial treatment Baseline PSA (ng/mL) 605 97 1,193 227 176 950 63 124 Cycles 4 4 4 6 6 6 6 6 Posttherapy PSA (ng/mL) <0.03 16 18 5 1 35 8 3 Maximum PSA response −100% −78% −98% −96% −98% −94% −87% −97% Free interval Time (mo) 14.7 5.1 3.8 6.7 4.9 4.9 6.9 5.7 Other therapies ADT ADT ADT ADT ADT ADT ADT ADT Rechallenge Age (y) 72 67 73 75 70 62 75 77 ECOG score 0 1 1 1 1 2 1 1 Sites of metastases Bone + + + + + + + − Lymph node + + − + − + + + Viscera − Lung − Adrenal − − − − Baseline PSA (ng/mL) 5 54 66 50 51 2,328 34 110 Cycles 4 2 2 1 2 3 2 2 Maximum PSA response −97% 83% −40% −37% −84% −67% 32% −47% PSMA PET/CT response PR − PR PD PR PD PD PD Therapy discontinuation Therapy break after excellent response Tumor progress Toxicity Toxicity Toxicity Tumor progress Tumor progress Toxicity ↵* Patients underwent initial docetaxel and docetaxel rechallenge.
↵† IGF-1R-antibody (NCT00313781), cabozantinib (COMET-1 Trial, NCT01605227).
LN = lymph node; RP = radical prostatectomy; RT = local radiotherapy; ADT = continuous androgen deprivation therapy; ECOG = Eastern Cooperative Oncology Group; PR = partial response; PD = progressive disease.
- TABLE 2
Adverse Events at 177Lu-PSMA-I&T Rechallenge Graded According to Common Terminology Criteria for Adverse Events, Version 5.0
Event Grade 1 Grade 2 Grade 3 Grade 4 Anemia 4 1 Leukopenia 2 2 Thrombopenia 1 2 Renal function impairment 1 Xerostomia 2
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
- Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
- Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
- Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy